When Serge Saxonov and Ben Hindson, co-founders of 10x Genomics, came to us in 2013, the two had a clear vision of how to engineer and produce cell-level sequencing machines. Since then, 10x has become a leading innovator in the field of cell sequencing, and its machines have become standard equipment in leading research labs.
Although he was an English major at Yale, Andrew Kress has long been a pioneer in finding, merging and utilizing healthcare data sets. As artificial intelligence makes such data a crucial resource in drug discovery, Andrew co-founded HealthVerity to provide the ideal platform and marketplace for data aggregation.
Charles Homcy, co-founder and chief executive of Maze Therapeutics, has spent his life combining brilliant insights with extraordinary executives teams, and we believe he has done it again with Maze. Maze focuses on gene modifiers (the social media influencers of the genetic code) to accelerate the discovery of drug targets for Mendelian diseases.
In 2011, we decided that Intarcia’s GLP-1 implant was an ideal solution to mitigate the suffering and costs from managing Type 2 diabetes. We have steadfastly supported the company through large-scale clinical registration studies, and Kurt Graves, Intarcia’s chairman and CEO, has shown remarkable tenacity preparing for a major commercial launch.
We believe Steve Kaldor, co-founder and chief executive of Kinnate Therapeutics, is one of the world’s most accomplished drug hunters and is creating drugs to target resistant cancers.
Rick Klausner, the founder and chief executive of Lyell Immunpharma, has a genius for seeing just over the scientific horizon and organizing the perfect teams to get there. We believe Lyell’s focus on developing cell-based immunotherapies for solid tumors shows every promise of being Rick’s most consequential venture ever.
“Foresite Capital has been a key partner during all parts of our growth over the years."
Kurt Graves, Chairman, President & CEO
"Foresite Capital has been a visionary partner."
Serge Saxonov, CEO & Co-Founder
"While we obviously value the financial component of Foresite Capital's support, the greatest value comes from their genuine commitment to being a part of our team."
Terry Rosen, CEO
"We have had the opportunity to work with a broad array of investors, but Foresite Capital distinguished itself from the pack as being an investor with a unique level of insight and access."
Othman Laraki, Co-Founder
"Foresite Capital uniquely understands data and biology."
